Blocking vascular endothelial growth factor (VEGF) signaling could normalize tumor vessels in various tumors and anti‐angiogenic agents have been approved for the treatment of NSCLC and significantly decrease the mortality risk [250]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.